WAVEMAN · COMPANY

NEO · Neogenomics Inc

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

NEO

Name: NEOGENOMICS INC (NEO) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

NEOGENOMICS INC

PHARMA & BIOTECH · SERVICES-TESTING LABORATORIES · CIK 0001077183

FORM 144 · 2☆ WATCH

INSIDER NET · 180D

-$440.2K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

158

13F, latest reported quarter

REVENUE GROWTH

+10.1%

XBRL, annual

NET MARGIN

-14.9%

CONVERSIONS · 180D

codes C/M, not in net · $0 priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$440.2K over 180 days

-$440.2K over 90 days

below 55% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

158 funds added or opened last quarter

more than 80% of Pharma & Biotech

REVENUE

+10.1% year over year

more than 60% of Pharma & Biotech

MARGIN

-14.9% net margin

more than 52% of Pharma & Biotech

BUYBACKS

$25.0M repurchased, FY to 2026-06-30

below 60% of Pharma & Biotech

SHORT

12.0% of shares outstanding short · 4.2 days to cover · settled 2026-07-31

more than 83% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

158 funds added or opened positions in the latest 13F quarter, of 269 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +98.2%

+98.2%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $440.2K sold by insiders over 180 days, 158 funds added last quarter, $4.0M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, NEOGENOMICS INC insiders sold a net $440.2K of stock across 29 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Aunan Greg D

Chief Accounting Officer

SELL

2026-08-04

20,000.0

$321.4K

TETRAULT LYNN A.

Director

SELL

2026-06-15

5,307.0

$58.9K

TETRAULT LYNN A.

Director

SELL

2026-06-09

5,307.0

$59.9K

Stone Warren

Pres & Chief Operating Officer

SELL

2026-01-20

22,128.0

$276.6K

Olivo Alicia C

EVP, GC & Business Development

SELL

2025-11-25

20,916.0

$251.0K

29 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 24 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

20,868,362.0 sh

$304.5M

First Light Asset Management, LLC

12,279,523.0 sh

$179.2M

FIRST TRUST ADVISORS LP

10,113,261.0 sh

$147.6M

Greenhouse Funds LLLP

8,574,210.0 sh

$125.1M

VANGUARD PORTFOLIO MANAGEMENT LLC

8,061,362.0 sh

$117.6M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

GREG AUNAN

FILED 2026-08-04

$321.5K

JEFFREY SHERMAN

FILED 2026-07-30

$3.7M

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Baird Equity Opportunity Fund

$2.0M POSITION · AS OF 2026-03-31

3.0%

First Trust NYSE Arca Biotechnology Index Fund

$45.5M POSITION · AS OF 2026-03-31

2.0%

State Street(R) SPDR(R) S&P(R) Health Care Services ETF

$1.4M POSITION · AS OF 2026-03-31

1.8%

FULLERTHALER BEHAVIORAL MICRO-CAP EQUITY FUND

$247.3K POSITION · AS OF 2026-03-31

1.1%

Advent Convertible Bond ETF

$318.3K POSITION · AS OF 2026-02-28

1.1%

Small Cap Equity Portfolio

$10.7M POSITION · AS OF 2026-04-30

1.1%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$727.3M	$660.6M	$591.6M	$509.7M
GROSS PROFIT	$314.3M	$290.1M	$244.6M	$187.9M
OPERATING INCOME	$-115.9M	$-92.1M	$-107.7M	$-157.6M
NET INCOME	$-108.0M	$-79.0M	$-88.0M	$-144.0M
OPERATING CASH FLOW	$5.2M	$7.0M	$-2.0M	$-66.0M
CASH	$159.6M	$367.0M	$342.5M	$263.2M
LONG-TERM DEBT	$341.9M	$340.3M	$538.2M	—

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE